July 23, 2014 4:54 AM ET

Healthcare Providers and Services

Company Overview of Alliance Healthcare Deutschland AG

Company Overview

Alliance Healthcare Deutschland AG engages in the wholesale trade of pharmaceutical products to pharmacies and hospitals in Germany and internationally. The company also offers logistics concepts and services for healthcare and pharmaceutical industries; engages in the design and implementation of integrated marketing, distribution, and logistics services for suppliers of health, cosmetics, and care products; and provides inventory and accounting, warehousing and distribution, complaint processing, return management, and hotline services. In addition, it provides market research services to the pharmaceutical manufacturers, pharmaceutical wholesale trade customers, and information service pr...

Solmsstrasse 25

Frankfurt am Main,  60486

Germany

2,892 Employees

Phone:

49 697 92030

Fax:

49 697 9203369

Key Executives for Alliance Healthcare Deutschland AG

Chairman of the Executive Board and Chairman of Executive Committee
Head of Account System & Finances and Member of Executive Committee
Personnel & Operations Director
Member of The Executive Board and Labour Relations Director
Age: 51
Commerce & Services Director
Compensation as of Fiscal Year 2014.

Alliance Healthcare Deutschland AG Key Developments

Andreae-Noris Zahn AG Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2012

Andreae-Noris Zahn AG reported consolidated earnings results for the nine months ended December 31, 2012. Sales revenues increased against the comparative prior year period by EUR 10.0 million or 0.3% from EUR 3,317.3 million to EUR 3,327.3 million. Lower other operating income, which was impacted comparatively by the release of valuation allowances in the prior year lower personnel expenses, as well as lower other operating expenses due to cost savings, resulted in earnings before interest and taxes (EBIT) of EUR 46.0 million which were EUR 20.9 million above the result of the comparative prior year period of EUR 25.1 million. However, the impact of restructuring costs in the prior year must be taken into account in this comparison. The financial result improved from loss of EUR 20.4 million to loss of EUR 11.2 million. This is attributable to a decline in interest expenses in connection with the refinancing of the KfW loan and the repayment of the promissory note loans, as well as lower dividend payments to minority shareholders with put options. Overall, earnings before taxes (EBT) rose by EUR 30.1 million from EUR 4.7 million to EUR 34.8 million. With tax expenses of EUR 9.3 million, the consolidated profit increased by EUR 22.2 million to EUR 25.5 million against EUR 3.3 million last year. The earnings per share (both diluted and undiluted) amounted to EUR 2.39 compared with EUR 0.32 during the prior year period. In accordance with the requirements of IAS 8.29, the adjustment in reporting has had an effect on the corresponding comparative period insofar as the cash flow from operating activities improved by EUR 9.6 million to cash used in operating activities of EUR 53.3 million. Mainly due to seasonally higher inventories, the cash used in operating activities amounted to EUR 13.4 million against EUR 53.3 million last year. The cash flow used in investment activities amounted to EUR 6.8 million against EUR 11.0 million last year. This related primarily to investments in buildings and the car fleet.

Andreae-Noris Zahn AG, Special/Extraordinary Shareholders Meeting, Dec 18, 2012

Andreae-Noris Zahn AG, Special/Extraordinary Shareholders Meeting, Dec 18, 2012.

Andreae-Noris Zahn AG Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2012; Reaffirms Earnings Guidance for the Fiscal 2013

Andreae-Noris Zahn AG reported unaudited consolidated earnings results for the first quarter ended June 30, 2012. For the quarter, the group's consolidated sales revenues increased versus the comparative prior year period by EUR 26.3 million, from EUR 1,080.0 million to EUR 1,106.3 million. This corresponds to a 2.4% rise. Lower other operating income due to the discontinuation of valuation effects, higher personnel expenses as well as lower operating expenses due to cost savings resulted in earnings before interest and taxes (EBIT) of EUR 18.3 million, that means EUR 5.4 million higher than during the comparative period (EUR 12.9 million). The financial result improved by EUR 3.1 million and amounted to EUR 2.1 million from EUR 5.2 million in a year ago. This was mainly attributable to a decline in interest expenses versus the comparative period, in connection with the refinancing of the KfW loan and the promissory note loans. Earnings before taxes (EBT) rose altogether from EUR 7.7 million by EUR 8.5 million to EUR 16.2 million. Consolidated result rose by EUR 6.2 million to EUR 12.4 million from EUR 6.2 million. Earnings per share (both diluted and undiluted) amounted to EUR 1.16 after EUR 0.59 during the comparative period. Mainly due to seasonally higher inventories, the cash flow from operating activities amounted to EUR 0.5 million during the reporting period. Consequently, it was EUR 29.5 million better than during the comparative period against EUR 29.0 million. The assessment of the essential opportunities and risks has not changed compared to the last consolidated management report. The result forecast for the full financial year 2013 remains likewise unchanged.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
October 28, 2013
Farmexpert DCI S.A.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Alliance Healthcare Deutschland AG, please visit www.anzag.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.